CHIC2

Summary

CHIC2 (cysteine rich hydrophobic domain 2, HGNC:1935) is a protein-coding gene on chromosome 4q12, encoding Cysteine-rich hydrophobic domain-containing protein 2 (Q9UKJ5).

This gene encodes a member of the CHIC family of proteins. The encoded protein contains a cysteine-rich hydrophobic (CHIC) motif, and is localized to vesicular structures and the plasma membrane. This gene is associated with some cases of acute myeloid leukemia.

Source: NCBI Gene 26511 — RefSeq curated summary.

At a glance

• Gene–disease (curated): acute myeloid leukemia (No Known Disease Relationship, GenCC)
• GWAS associations: 12
• Clinical variants (ClinVar): 21 total
• Phenotypes (HPO): 3
• MANE Select transcript: NM_012110

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1935
Approved symbol	CHIC2
Name	cysteine rich hydrophobic domain 2
Location	4q12
Locus type	gene with protein product
Status	Approved
Aliases	BTL
Ensembl gene	ENSG00000109220
Ensembl biotype	protein_coding
OMIM	604332
Entrez	26511

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 3 protein_coding, 1 retained_intron

ENST00000263921, ENST00000509678, ENST00000510894, ENST00000512964

RefSeq mRNA: 1 — MANE Select: NM_012110 NM_012110

CCDS: CCDS3493

Canonical transcript exons

ENST00000263921 — 6 exons

Exon	Start	End
ENSE00000715419	54048955	54049110
ENSE00000877906	54064182	54064605
ENSE00001122093	54013837	54013896
ENSE00001126708	54009789	54010145
ENSE00001607014	54014063	54014119
ENSE00003502630	54049251	54049305

Expression profiles

Bgee: expression breadth ubiquitous, 268 present calls, max score 93.41.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 48.0487 / max 518.1826, expressed in 1819 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
52138	33.1787	1815
52139	9.1722	1787
52136	4.5072	1230
52137	0.7850	358
52140	0.3336	145
52135	0.0720	28

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right testis	UBERON:0004534	93.41	gold quality
left testis	UBERON:0004533	92.93	gold quality
stromal cell of endometrium	CL:0002255	92.78	gold quality
blood	UBERON:0000178	92.55	gold quality
lower esophagus mucosa	UBERON:0035834	92.32	gold quality
testis	UBERON:0000473	91.73	gold quality
adult organism	UBERON:0007023	91.63	gold quality
calcaneal tendon	UBERON:0003701	91.39	gold quality
cartilage tissue	UBERON:0002418	91.37	gold quality
monocyte	CL:0000576	90.79	gold quality
bone marrow	UBERON:0002371	90.78	gold quality
mononuclear cell	CL:0000842	90.56	gold quality
right lung	UBERON:0002167	90.51	gold quality
leukocyte	CL:0000738	90.50	gold quality
thymus	UBERON:0002370	90.37	gold quality
skin of leg	UBERON:0001511	90.21	gold quality
decidua	UBERON:0002450	90.21	gold quality
upper leg skin	UBERON:0004262	90.12	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	89.83	gold quality
skin of abdomen	UBERON:0001416	89.62	gold quality
esophagus mucosa	UBERON:0002469	89.48	gold quality
zone of skin	UBERON:0000014	89.45	gold quality
corpus epididymis	UBERON:0004359	89.21	gold quality
oral cavity	UBERON:0000167	88.82	gold quality
caput epididymis	UBERON:0004358	88.79	gold quality
bronchial epithelial cell	CL:0002328	88.75	gold quality
penis	UBERON:0000989	88.63	gold quality
upper arm skin	UBERON:0004263	88.23	gold quality
jejunal mucosa	UBERON:0000399	88.20	gold quality
tendon	UBERON:0000043	88.06	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	13.03

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

73 targeting CHIC2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-767-5P	99.95	70.85	993
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488
HSA-MIR-548I	99.94	71.25	3481
HSA-MIR-548J-5P	99.94	71.14	3489
HSA-MIR-548O-5P	99.94	71.24	3488

Literature-anchored findings (GeneRIF, showing 2)

• used fluorescence in situ hybridization to detect deletion of the CHIC2 locus at 4q12 as a surrogate for the FIP1L1-PDGFRA fusion and was observed in bone marrow cells for 3 of 5 patients with systemic mast cell disease associated with eosinophilia (PMID:12842979)
• studied a new FISH method to detect CHIC2 deletion, FIP1L1/PDGFRA fusion and PDGFRA translocation in patients with myeloid neoplasms associated with eosinophilia (PMID:19118897)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	chic2	ENSDARG00000022690
mus_musculus	Chic2	ENSMUSG00000029229
rattus_norvegicus	Chic2	ENSRNOG00000002267
drosophila_melanogaster	CG5938	FBGN0046247
caenorhabditis_elegans		WBGENE00044319

Paralogs (1): CHIC1 (ENSG00000204116)

Protein

Protein identifiers

Cysteine-rich hydrophobic domain-containing protein 2 — Q9UKJ5 (reviewed: Q9UKJ5)

Alternative names: BrX-like translocated in leukemia

All UniProt accessions (3): Q9UKJ5, D6RDW7, H0Y8H1

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Cell membrane. Cytoplasmic vesicle.

Post-translational modifications. Palmitoylation in the CHIC motif is required for membrane association.

Disease relevance. A chromosomal aberration involving CHIC2 is found in a form of acute myeloid leukemia (AML). Translocation t(4;12)(q12;p13) with ETV6.

Similarity. Belongs to the CHIC family.

RefSeq proteins (1): NP_036242* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR019383	Golgin_A_7/ERF4	Domain
IPR039735	CHIC1/2	Family

Pfam: PF10256

UniProt features (5 total): chain 1, coiled-coil region 1, short sequence motif 1, site 1, mutagenesis site 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
8SUV	X-RAY DIFFRACTION	1.63

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UKJ5-F1	84.67	0.50

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 111–112 (breakpoint for translocation to form chic2-etv6 in aml)

Mutagenesis-validated functional residues (1):

Position	Phenotype
88–95	loss of palmitoylation. abolishes membrane association.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 173 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_UP, GSE45365_NK_CELL_VS_BCELL_UP, TGGTGCT_MIR29A_MIR29B_MIR29C, GTGCCTT_MIR506, GROSS_HYPOXIA_VIA_ELK3_DN, GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_UP, GOCC_GOLGI_ASSOCIATED_VESICLE, TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_DUCTAL_NORMAL_DN, MAF_Q6, RYTTCCTG_ETS2_B, CREBP1_01, VANTVEER_BREAST_CANCER_ESR1_DN, MARSON_BOUND_BY_FOXP3_STIMULATED, WGGAATGY_TEF1_Q6, E4BP4_01

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (5): Golgi apparatus (GO:0005794), Golgi-associated vesicle (GO:0005798), plasma membrane (GO:0005886), membrane (GO:0016020), cytoplasmic vesicle (GO:0031410)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	2
binding	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cytoplasmic vesicle	1
membrane	1
cell periphery	1
cellular anatomical structure	1
intracellular vesicle	1

Protein interactions and networks

STRING

436 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CHIC2	ETV6	P41212	852
CHIC2	FIP1L1	Q6UN15	766
CHIC2	PDGFRA	P16234	572
CHIC2	LGALS4	P56470	507
CHIC2	GSX2	Q9BZM3	425
CHIC2	FGF10	O15520	410
CHIC2	LNX1	Q8TBB1	409
CHIC2	PDGFRB	P09619	398
CHIC2	FGF5	P12034	377
CHIC2	FGF9	P31371	377
CHIC2	FGF7	P21781	371
CHIC2	FGF8	P55075	369
CHIC2	SCFD2	Q8WU76	367
CHIC2	FGFR1	P11362	356
CHIC2	FGF18	O76093	355
CHIC2	FGF3	P11487	355

IntAct

210 interactions, top by confidence:

A	B	Type	Score
CHIC2	CDR2	psi-mi:“MI:0915”(physical association)	0.780
CDR2	CHIC2	psi-mi:“MI:0915”(physical association)	0.780
CHIC2	KRTAP5-9	psi-mi:“MI:0915”(physical association)	0.720
KRTAP10-8	CHIC2	psi-mi:“MI:0915”(physical association)	0.720
CHIC2	KRTAP10-8	psi-mi:“MI:0915”(physical association)	0.720
KRTAP5-9	CHIC2	psi-mi:“MI:0915”(physical association)	0.720
HOXA1	CHIC2	psi-mi:“MI:0915”(physical association)	0.670
CATSPER1	CHIC2	psi-mi:“MI:0915”(physical association)	0.670
OTX1	CHIC2	psi-mi:“MI:0915”(physical association)	0.670
UBE2N	UBA1	psi-mi:“MI:0914”(association)	0.640
CHIC2	PLEKHF2	psi-mi:“MI:0915”(physical association)	0.620
MEOX2	CHIC2	psi-mi:“MI:0915”(physical association)	0.560
CHIC2		psi-mi:“MI:0915”(physical association)	0.560
	CHIC2	psi-mi:“MI:0915”(physical association)	0.560
TCF4	CHIC2	psi-mi:“MI:0915”(physical association)	0.560
KRTAP10-7	CHIC2	psi-mi:“MI:0915”(physical association)	0.560
KRTAP10-9	CHIC2	psi-mi:“MI:0915”(physical association)	0.560
FLJ13057	CHIC2	psi-mi:“MI:0915”(physical association)	0.560
CHIC2	KRT40	psi-mi:“MI:0915”(physical association)	0.560
NOTCH2NLA	CHIC2	psi-mi:“MI:0915”(physical association)	0.560
CBY2	CHIC2	psi-mi:“MI:0915”(physical association)	0.560
CHIC2	PNMA1	psi-mi:“MI:0915”(physical association)	0.560
CHIC2	KRTAP4-2	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (99): CHIC2 (Two-hybrid), CHIC2 (Two-hybrid), CHIC2 (Two-hybrid), CHIC2 (Two-hybrid), CHIC2 (Two-hybrid), GMCL1 (Two-hybrid), CEP44 (Two-hybrid), KRTAP4-2 (Two-hybrid), KRT40 (Two-hybrid), SPERT (Two-hybrid), KRTAP10-7 (Two-hybrid), KRTAP10-9 (Two-hybrid), KRTAP10-1 (Two-hybrid), KRTAP10-8 (Two-hybrid), KRTAP10-3 (Two-hybrid)

ESM2 similar proteins: A0A8I6A2H6, A2A7Q9, A7E2I7, F1M8G0, O08873, O14795, P17863, P49140, P49805, P54368, P55814, Q05DH4, Q08B84, Q2M146, Q3C2P8, Q49LS4, Q4KUS2, Q505K2, Q5GH67, Q5GH76, Q5RDN2, Q5RH73, Q5TF58, Q5VXU3, Q5ZKN3, Q62739, Q62768, Q62769, Q66JG9, Q68FE7, Q6NRE7, Q6NYK3, Q7Z698, Q86XE3, Q8CB19, Q8CBW7, Q8CDD8, Q8IW70, Q8R2V2, Q8WXG6

Diamond homologs: Q5VXU3, Q8CBW7, Q9D9G3, Q9UKJ5

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 62 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Keratinization	19	25.8×	6e-21
Formation of the cornified envelope	9	19.3×	3e-08

GO biological processes:

GO term	Partners	Fold	FDR
keratinization	9	42.1×	2e-10

Disease & clinical

Clinical variants and AI predictions

ClinVar

21 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	11
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1536 predictions. Top by Δscore:

Variant	Effect	Δscore
4:54013894:CAG:C	acceptor_gain	1.0000
4:54014058:CTCA:C	donor_loss	1.0000
4:54014059:TCACC:T	donor_loss	1.0000
4:54014060:CAC:C	donor_loss	1.0000
4:54014061:ACC:A	donor_loss	1.0000
4:54014120:C:CC	acceptor_gain	1.0000
4:54020495:A:AG	acceptor_gain	1.0000
4:54020495:ACT:A	acceptor_gain	1.0000
4:54020496:C:G	acceptor_gain	1.0000
4:54048947:CAACT:C	donor_loss	1.0000
4:54048948:AACTT:A	donor_loss	1.0000
4:54048949:ACTTA:A	donor_loss	1.0000
4:54048950:CTTAC:C	donor_loss	1.0000
4:54048951:TTACT:T	donor_loss	1.0000
4:54048952:TACT:T	donor_loss	1.0000
4:54048953:A:AC	donor_gain	1.0000
4:54048953:ACT:A	donor_gain	1.0000
4:54048953:ACTCT:A	donor_loss	1.0000
4:54048954:C:CT	donor_gain	1.0000
4:54048954:CT:C	donor_gain	1.0000
4:54048954:CTC:C	donor_gain	1.0000
4:54048954:CTCT:C	donor_gain	1.0000
4:54049106:GCTAC:G	acceptor_loss	1.0000
4:54049107:CTAC:C	acceptor_gain	1.0000
4:54049108:TAC:T	acceptor_gain	1.0000
4:54049109:ACC:A	acceptor_loss	1.0000
4:54049111:CTAA:C	acceptor_loss	1.0000
4:54049112:T:A	acceptor_loss	1.0000
4:54049243:ACACT:A	donor_loss	1.0000
4:54049244:CACT:C	donor_loss	1.0000

AlphaMissense

1086 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:54013884:A:G	W134R	1.000
4:54013884:A:T	W134R	1.000
4:54013889:A:G	L132S	1.000
4:54048985:A:C	S100R	1.000
4:54048985:A:T	S100R	1.000
4:54048987:T:G	S100R	1.000
4:54049011:A:G	C92R	1.000
4:54049019:C:T	G89D	1.000
4:54049020:C:G	G89R	1.000
4:54049032:A:G	W85R	1.000
4:54049032:A:T	W85R	1.000
4:54049061:A:G	L75P	1.000
4:54049073:A:T	V71D	1.000
4:54049084:G:C	S67R	1.000
4:54049084:G:T	S67R	1.000
4:54049086:T:G	S67R	1.000
4:54049094:A:G	F64S	1.000
4:54049261:A:G	L55S	1.000
4:54049285:A:G	F47S	1.000
4:54049297:A:G	L43P	1.000
4:54049300:C:T	G42E	1.000
4:54013895:A:G	L130P	0.999
4:54014071:A:C	Y127D	0.999
4:54014081:G:C	N123K	0.999
4:54014081:G:T	N123K	0.999
4:54014082:T:A	N123I	0.999
4:54014094:A:G	L119S	0.999
4:54048977:G:C	P103R	0.999
4:54048977:G:T	P103Q	0.999
4:54048981:A:G	W102R	0.999

dbSNP variants (sampled 300 via entrez): RS1000036635 (4:54020577 C>A), RS1000049899 (4:54059456 C>G,T), RS1000055839 (4:54014848 T>A), RS1000079231 (4:54059789 C>A), RS1000112420 (4:54083747 G>C), RS1000140375 (4:54029138 A>C,G), RS1000149790 (4:54026239 GT>G,GTT), RS1000183977 (4:54021331 A>G), RS10002384 (4:54060870 T>G), RS1000282390 (4:54065760 A>G), RS1000292363 (4:54059676 A>G), RS1000342960 (4:54078583 T>G), RS1000368211 (4:54088026 A>G), RS1000370706 (4:54014301 A>C,T), RS1000396263 (4:54052869 A>G)

Disease associations

OMIM: gene MIM:604332 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
acute myeloid leukemia	No Known Disease Relationship	Unknown

Mondo (1): acute myeloid leukemia (MONDO:0018874)

Orphanet (0):

HPO phenotypes

3 total (3 of 3 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0001442	Typified by somatic mosaicism
HP:0004808	Acute myeloid leukemia

GWAS associations

12 associations (top):

Study	Trait	p-value
GCST001235_2	Blood pressure	1.000000e-08
GCST003264_80	Post bronchodilator FEV1/FVC ratio	2.000000e-06
GCST004775_19	Pulse pressure	2.000000e-10
GCST007705_74	Pulse pressure	5.000000e-16
GCST007705_76	Pulse pressure	7.000000e-13
GCST009240_402	Serum metabolite levels (CMS)	2.000000e-10
GCST009391_1161	Metabolite levels	2.000000e-06
GCST009391_888	Metabolite levels	9.000000e-06
GCST010699_1	Brain morphology (min-P)	3.000000e-11
GCST010701_128	Cortical surface area (MOSTest)	2.000000e-10
GCST010702_22	Subcortical volume (MOSTest)	5.000000e-50
GCST010703_288	Brain morphology (MOSTest)	5.000000e-15

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0005763	pulse pressure measurement
EFO:0004713	FEV/FVC ratio
EFO:0010460	anthranilic acid measurement
EFO:0010439	triacylglycerol 58:12 measurement
EFO:0004346	neuroimaging measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D015470	Leukemia, Myeloid, Acute	C04.557.337.539.275; C15.378.508.539.275

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs871606	CHIC2		0.00	0

CTD chemical–gene interactions

51 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	affects expression, increases abundance, increases expression, decreases expression	3
Cyclosporine	increases expression	3
bisphenol A	affects expression, decreases expression	2
Valproic Acid	decreases methylation, increases expression	2
Particulate Matter	increases abundance, increases expression, decreases expression	2
aristolochic acid I	increases expression	1
GSK-J4	increases expression	1
bisphenol F	affects cotreatment, increases expression	1
triphenyl phosphate	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	increases expression	1
cobaltous chloride	increases expression	1
potassium chromate(VI)	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
chloropicrin	increases expression	1
K 7174	increases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	increases expression	1
abrine	increases expression	1
(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II)	increases expression	1
bisphenol S	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, decreases expression	1
NSC 689534	affects binding, increases expression	1
Arsenic	decreases ubiquitination	1
Atrazine	increases expression	1
Benzo(a)pyrene	increases expression	1
Calcitriol	increases expression	1
Carbamazepine	affects expression	1
Cisplatin	decreases expression, affects cotreatment	1
Copper	affects binding, increases expression	1
Dexamethasone	affects cotreatment, increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00199147	PHASE4	UNKNOWN	Efficacy of G-CSF-Priming in Elderly AML Patients
NCT00304447	PHASE4	COMPLETED	Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia
NCT00464217	PHASE4	COMPLETED	Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years
NCT00487448	PHASE4	COMPLETED	SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia
NCT00488709	PHASE4	COMPLETED	Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT00686543	PHASE4	COMPLETED	Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)
NCT01041040	PHASE4	COMPLETED	LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)
NCT01198054	PHASE4	TERMINATED	LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)
NCT01200355	PHASE4	COMPLETED	Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome
NCT01347996	PHASE4	COMPLETED	Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia
NCT01587430	PHASE4	UNKNOWN	3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia
NCT01819792	PHASE4	COMPLETED	Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia
NCT02024308	PHASE4	UNKNOWN	AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy
NCT02027064	PHASE4	UNKNOWN	Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT
NCT02277847	PHASE4	UNKNOWN	Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia
NCT02386800	PHASE4	ACTIVE_NOT_RECRUITING	CINC424A2X01B Rollover Protocol
NCT02926586	PHASE4	COMPLETED	Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML
NCT02933333	PHASE4	UNKNOWN	G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor
NCT03026842	PHASE4	UNKNOWN	Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21)
NCT03150134	PHASE4	UNKNOWN	Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients
NCT05144243	PHASE4	ACTIVE_NOT_RECRUITING	Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China
NCT06370000	PHASE4	RECRUITING	Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality
NCT06571825	PHASE4	RECRUITING	RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
NCT07016165	PHASE4	RECRUITING	Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies
NCT07044687	PHASE4	RECRUITING	Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
NCT07486713	PHASE4	RECRUITING	Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
NCT07561892	PHASE4	RECRUITING	Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).
NCT00000589	PHASE3	COMPLETED	Trial to Reduce Alloimmunization to Platelets (TRAP)
NCT00044486	PHASE3	COMPLETED	Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)
NCT00093990	PHASE3	COMPLETED	Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT00125606	PHASE3	TERMINATED	Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide
NCT00136084	PHASE3	COMPLETED	Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
NCT00146120	PHASE3	COMPLETED	Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result
NCT00150878	PHASE3	TERMINATED	Standard vs. Reduced-Intensity Conditioning in Patients With Acute Myeloid Leukemia in First Remission
NCT00151255	PHASE3	COMPLETED	All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00152139	PHASE3	COMPLETED	Stem Cell Transplantation for Patients With Hematologic Malignancies
NCT00152594	PHASE3	TERMINATED	Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia
NCT00186966	PHASE3	COMPLETED	Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia
NCT00226512	PHASE3	WITHDRAWN	To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning
NCT00260832	PHASE3	COMPLETED	Trial of Decitabine in Patients With Acute Myeloid Leukemia